Friday, July 10, 2026

biotech · Propionic Acidemia · Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

SOM Biotech

Moderna Biotech Spain is a biotech organization headquartered in EU. Primary therapeutic focus areas include Propionic Acidemia, Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency, Glycogen storag

Barcelona, ES HQ
2009 Founded
14 Employees
EMA registrant Type
Company details
Clinical program

DAN-COVID

Approved · small molecule · SARS-CoV-2 infection

DAN-COVID for SARS-CoV-2 infection is a Approved program (small_molecule) at Moderna Biotech Spain with 1 ClinicalTrials.gov record(s).

← All Moderna Biotech Spain projects Approved small molecule active

Internal code DAN-COVID

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Moderna Biotech Spain
Phase
Approved
Modality
small_molecule
Indication
SARS-CoV-2 infection
Status
active
Trials
1